Arterra Bioscience SpA(IT:ARBS)
€3.02-0.05 (-1.63%)
IT:ARBS
Arterra Bioscience SpA financials statements
€3.02
At close:-0.05 (-1.63%)
Arterra Bioscience SpA (ARBS) Ratios
0 Followers
Arterra Bioscience SpA Ratios
IT:ARBS's free cash flow for Q2 2026 was €877.35K. For the 2026 fiscal year, IT:ARBS's free cash flow was decreased by €-327.48K and operating cash flow was €1.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.74 | 9.99 | 9.35 | 8.49 | 12.08 |
| Quick Ratio | 5.99 | 8.37 | 7.74 | 7.49 | 11.39 |
| Cash Ratio | 1.52 | 4.06 | 4.37 | 3.80 | 6.85 |
| Solvency Ratio | 1.14 | 0.85 | 0.89 | 0.93 | 0.76 |
| Operating Cash Flow Ratio | 2.26 | 1.29 | 1.22 | 1.21 | 1.99 |
| Short-Term Operating Cash Flow Coverage | 21.32 | 11.04 | 11.88 | 8.01 | 6.26 |
| Net Current Asset Value | € 4.82M | € 6.25M | € 6.08M | € 7.70M | € 6.38M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.03 | 0.04 | 0.05 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.03 | 0.04 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 |
| Financial Leverage Ratio | 1.16 | 1.17 | 1.17 | 1.20 | 1.22 |
| Debt Service Coverage Ratio | 9.44 | 17.17 | 16.80 | 10.74 | 6.93 |
| Interest Coverage Ratio | 667.15 | 1075.94 | -35.56 | 48.60 | 235.30 |
| Debt to Market Cap | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest Debt Per Share | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 |
| Net Debt to EBITDA | -1.23 | -1.46 | -1.79 | -1.67 | -2.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 15.87% | 87.46% | 55.46% | 13.72% | 14.19% |
| EBIT Margin | 12.73% | 40.81% | 39.33% | 50.26% | 26.98% |
| EBITDA Margin | 18.97% | 48.94% | 55.29% | 65.07% | 37.26% |
| Operating Profit Margin | 12.73% | 35.19% | -10.69% | 10.16% | 40.47% |
| Pretax Profit Margin | 42.97% | 40.77% | 39.03% | 50.05% | 26.81% |
| Net Profit Margin | 43.15% | 32.03% | 32.26% | 39.38% | 23.42% |
| Continuous Operations Profit Margin | 43.15% | 32.03% | 32.26% | 39.38% | 23.42% |
| Net Income Per EBT | 100.43% | 78.56% | 82.64% | 78.67% | 87.36% |
| EBT Per EBIT | 337.60% | 115.85% | -365.28% | 492.41% | 66.24% |
| Return on Assets (ROA) | 13.75% | 9.97% | 8.57% | 11.25% | 9.59% |
| Return on Equity (ROE) | 15.95% | 11.70% | 10.01% | 13.51% | 11.72% |
| Return on Capital Employed (ROCE) | 4.32% | 11.68% | -3.04% | 3.20% | 17.64% |
| Return on Invested Capital (ROIC) | 4.29% | 9.10% | -2.50% | 2.48% | 15.06% |
| Return on Tangible Assets | 13.77% | 10.00% | 8.60% | 11.29% | 9.70% |
| Earnings Yield | 9.98% | 10.24% | 9.74% | 9.83% | 5.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.33 | 1.29 | 1.66 | 1.35 | 1.49 |
| Payables Turnover | 16.26 | 1.90 | 5.95 | 16.35 | 12.60 |
| Inventory Turnover | 2.54 | 0.39 | 1.10 | 2.65 | 6.46 |
| Fixed Asset Turnover | 2.77 | 2.77 | 2.71 | 2.34 | 2.85 |
| Asset Turnover | 0.32 | 0.31 | 0.27 | 0.29 | 0.41 |
| Working Capital Turnover Ratio | 0.70 | 0.58 | 0.43 | 0.44 | 0.67 |
| Cash Conversion Cycle | 395.56 | 1018.32 | 490.96 | 385.31 | 273.00 |
| Days of Sales Outstanding | 274.42 | 282.68 | 219.28 | 270.09 | 245.51 |
| Days of Inventory Outstanding | 143.59 | 927.83 | 332.98 | 137.54 | 56.47 |
| Days of Payables Outstanding | 22.44 | 192.19 | 61.29 | 22.32 | 28.97 |
| Operating Cycle | 418.01 | 1210.51 | 552.25 | 407.63 | 301.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.30 | 0.16 | 0.15 | 0.21 | 0.21 |
| Free Cash Flow Per Share | 0.23 | 0.06 | 0.14 | 0.19 | 0.12 |
| Dividend Paid and CapEx Coverage Ratio | 1.53 | 0.80 | 1.37 | 3.23 | 2.29 |
| Capital Expenditure Coverage Ratio | 4.40 | 1.60 | 12.40 | 14.10 | 2.29 |
| Operating Cash Flow Coverage Ratio | 7.65 | 2.99 | 2.66 | 2.85 | 2.27 |
| Operating Cash Flow to Sales Ratio | 0.43 | 0.25 | 0.31 | 0.39 | 0.29 |
| Free Cash Flow Yield | 7.65% | 3.06% | 8.53% | 9.01% | 4.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.07 | 9.76 | 10.27 | 10.17 | 17.39 |
| Price-to-Sales (P/S) Ratio | 4.32 | 3.13 | 3.31 | 4.00 | 4.07 |
| Price-to-Book (P/B) Ratio | 1.60 | 1.14 | 1.03 | 1.37 | 2.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 13.07 | 32.67 | 11.72 | 11.09 | 24.51 |
| Price-to-Operating Cash Flow Ratio | 10.09 | 12.26 | 10.77 | 10.31 | 13.82 |
| Price-to-Earnings Growth (PEG) Ratio | 0.20 | 0.39 | -0.43 | 0.43 | 0.00 |
| Enterprise Value Multiple | 21.57 | 4.93 | 4.20 | 4.48 | 8.55 |
| Enterprise Value | 19.03M | 10.06M | 7.75M | 10.48M | 15.11M |
| EV to EBITDA | 21.57 | 4.93 | 4.20 | 4.48 | 8.55 |
| EV to Sales | 4.09 | 2.41 | 2.32 | 2.92 | 3.19 |
| EV to Free Cash Flow | 12.36 | 25.20 | 8.22 | 8.08 | 19.18 |
| EV to Operating Cash Flow | 9.55 | 9.46 | 7.56 | 7.51 | 10.82 |
| Tangible Book Value Per Share | 1.89 | 1.71 | 1.61 | 1.56 | 1.40 |
| Shareholders’ Equity Per Share | 1.89 | 1.72 | 1.61 | 1.57 | 1.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.21 | 0.17 | 0.21 | 0.13 |
| Revenue Per Share | 0.70 | 0.63 | 0.50 | 0.54 | 0.71 |
| Net Income Per Share | 0.30 | 0.20 | 0.16 | 0.21 | 0.17 |
| Tax Burden | 1.00 | 0.79 | 0.83 | 0.79 | 0.87 |
| Interest Burden | 3.38 | 1.00 | 0.99 | 1.00 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.48 | 0.00 | 0.46 | 0.00 |
| SG&A to Revenue | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.99 | 0.80 | 0.95 | 0.99 | 1.26 |
Currency in EUR
